As the annual J.P. Morgan HealthCare Conference kicked off Monday, two pharma giants unveiled deals that give them access to in-vivo gene editing technologies. Pfizer is teaming up with Beam Therapeutics to develop new base-editing therapies while Bayer hopes to develop new medicines with the in-vivo CRISPR editing tools of Mammoth Biosciences.
The Point of Base Editors: Correcting Point Mutations genengnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from genengnews.com Daily Mail and Mail on Sunday newspapers.
Company On-track to Submit First IND for BEAM-101 in the Second Half of 2021 Continued Progress Across Base Editing Portfolio, Including Initiation of.
CRISPR 2.0: Base Editing in the Groove
A series of exciting preclinical and animal model results show that base editing is making rapid strides toward the clinic
March 4, 2021
Researchers from the Broad Institute, the NIH, and Vanderbilt University have used an adenine base editor (ABE) to treat progeria in mice. Correcting the mutation that causes progeria led to strong symptom reduction and longer lifespan. An ABE is shown here bound to a guide RNA and a targeted piece of DNA. [Aditya Raguram, Liu Laboratory, Broad Institute]
Share
A reasonable idea, suggests Sekar Kathiresan, MD, co-founder and CEO of Verve Therapeutics, is the development of a one-time treatment a single spelling change in the DNA of a liver gene in an adult person that would “turn off the gene and lower blood cholesterol levels for the rest of the person’s life.” Although this idea would not have been taken very seriously 10 years ago, it is now being investigated. It is a potent illustration of the m